Negative feedback is among the key mechanisms for regulating receptor tyrosine kinase (RTK) signaling. Human Sef, a recently identified inhibitor of RTK signaling, encodes different isoforms, including a membrane spanning (hSef-a) and a cytosolic (hSef-b) isoform. Previously, we reported that hSef-b inhibited fibroblast proliferation and prevented the activation of mitogen-activated protein kinase (MAPK), without affecting protein kinase B/Akt or p38 MAPK. Conflicting results were reported concerning hSef-a inhibition of MAPK activation, and the effect of hSef-a on other RTK-induced signaling pathways is unknown. Here we show that, in fibroblasts, similar to hSef-b, ectopic expression of hSef-a inhibited fibroblast growth factorinduced cell proliferation. Unlike hSef-b, however, the growth arrest was mediated via a MAPK-independent mechanism, and was accompanied by elevated p38 MAPK phosphorylation and inhibition of protein kinase B/Akt. In addition, hSef-a, but not hSef-b, mediated apoptosis in fibroblast growth factor-stimulated cells. Chemical inhibitor of p38 MAPK abrogated the effect of hSef-a on apoptosis. In epithelial cells, ectopic expression of hSef-a inhibited the activation of MAPK, whereas downregulation of endogenous hSef-a significantly increased MAPK activation and accelerated growth factor-dependent cell proliferation. These results indicate that hSef-a is a multifunctional negative modulator of RTK signaling and clearly demonstrate that hSef-a can inhibit the activation of MAPK, although in a cell type-specific manner. Moreover, the differences between the activities of hSef-a and hSef-b suggest that hSef isoforms can control signal specificity and subsequent cell fate by utilizing different mechanisms to modulate RTK signaling.
Growth factors represent a large group of ligands that bind and activate specific cell surface receptors endowed with tyrosine kinase activity (designated RTK) 5 (1). Ligand binding to RTK induces receptor dimerization and subsequent activation of the receptor tyrosine-kinase domain by autophosphorylation. Tyrosine phosphorylation of RTKs is crucial in recruiting and activating a variety of signaling molecules possessing intrinsic enzymatic activities or adapter proteins that link different proteins involved in signal transduction (1). These interactions then trigger a number of signaling cascades, including the mitogen-activated protein kinases (MAPKs) and the phosphatidylinositol 3-kinase (PI3K) cascades, which are primary components of this intracellular signaling machinery (1). All eukaryotic cells possess multiple MAPK pathways, of which the ERK/MAPK, the p38 MAPK, and the Jun kinase (JNK) have been extensively studied (2) . ERK/MAPKs are preferably activated by growth factors, whereas p38 MAPK and JNK are more responsive to environmental stress and inflammatory cytokines, but can be activated by growth factors as well (2) . The PI3K pathway transduces signals from a number of external stimuli, including growth factors, cytokines, and stress (3) .
Growth factor signaling by RTKs is essential for controlling fundamental biological processes, including cell proliferation and differentiation, cell migration, and survival. Deregulated RTK signaling has been associated with a variety of human diseases, including cancer, cardiovascular diseases, and skeletal disorders, implying that RTKs activities must be tightly constrained under physiological conditions (4 -7) . Several mechanisms collectively known as "negative signaling" have evolved to attenuate signaling by RTKs (8) . One such mode of regulation involves negative feedback loops that restrict the duration or intensity of RTK signals. Studies in the past decade have identified a number of feedback inhibitors for the Ras/MAPK pathway, including the Sproutys, the SPREDs (Sprouty-related EVH1-domain-containing), and Sef (similar expression to FGF genes) proteins. These proteins belong to a class of pathwayspecific antagonists whose expression and activity are induced by the pathway they inhibit (8 -10) .
Sef was originally identified in zebrafish (designated zfSef) as a specific inhibitor of FGF signaling and subsequently in mammals and chicken (11) (12) (13) (14) (15) (16) (17) . In addition to FGFs, mammalian Sef was reported to inhibit nerve growth factor and EGF signaling (13) (14) (15) (16) 18) . Unlike the Sproutys and the SPREDs that represent gene families, a single Sef gene exists in vertebrates. The prototypical Sef (designated zfSef, mSef, hSef-a, and cSef for zebrafish, mouse, human, and chicken Sef, respectively) encodes a membrane-spanning protein that is highly conserved throughout vertebrate evolution (17) . Its extracellular portion contains a single immunoglobulin-like domain and several potential sites for N-linked glycosylation. The intracellular portion has an interleukin 17 receptor-like domain and an invariant site for tyrosine phosphorylation. It has not been demonstrated whether this tyrosine residue undergoes phosphorylation. It is considered of functional importance, because its mutation in zfSef abrogated zfSef inhibitory activity (12) . Previously we have shown that an alternative splicing mechanism generates a cytosolic hSef isoform. In this isoform, termed hSef-b, the signal for secretion and nine N-terminal residues in hSef-a were substituted with a short stretch of new N-terminal residues (14) . hSef-b prevented FGF and platelet derived growth factor-induced cell proliferation by inhibiting the activation of ERK/MAPK (14) . The ability of the prototypical Sef to inhibit the activation of MAPK and its action point along the Ras/MAPK cascade are controversial. Several reports indicated that zfSef and hSef-a act at the level of, or downstream from, MEK, to inhibit the activation of MAPK (11, 15) . In contrast, other reports argued that mSef and hSef-a act upstream or at the level of Ras (13, 16, 19) . A recent study suggested that Sef does not inhibit the activation of MAPK but acts by preventing nuclear translocation of activated MAPK (18) .
In the present study, we employed ectopic hSef expression as well as RNA silencing to analyze the modulatory activities and mode of action of hSef-a. In addition, we investigated whether hSef variants can be phosphorylated on tyrosine as predicted from their sequence. Our results revealed that hSef-a, unlike hSef-b, is a multifunctional protein that modulates cell cycle progression and cell survival. Both hSef variants are phosphorylated on tyrosine in the presence of activated FGF receptor and most likely on several tyrosine residues.
EXPERIMENTAL PROCEDURES
Enzymes, Growth Factors, Reagents, and Chemicals-Restriction enzymes and enzymes used for cDNA cloning and plasmid construction were from New England Biolabs, Roche Applied Science, and Amersham Biosciences. Purified recombinant FGF-2 was produced as previously described (20) . Bovine brain FGF1, recombinant human FGF4, and epidermal growth factor (EGF) were from R&D Systems. [ 3 H]Thymidine (25 Ci/mmol) was from Amersham Biosciences HVD Biotech. Fibronectin, fetal and newborn calf serum, and media were from Biological Industries or from Invitrogen. Fluoromount-GTM was from Southern Biotechnology Associates, Inc. Bovine serum albumin was from ICN. Lipofectamine and Dreamfect transfection reagents were from Invitrogen and Ozbioscience, respectively. Insulin and other materials were from Sigma.
Construction of Mutants and Expression
Vectors-Isolation and cloning of hSef-a into pcDNA3.1/Myc-His(ϩ)B vector (Invitrogen) was described elsewhere (14) . For the Tet-off hSef expression system, hSef-a coding region was subcloned into the pTet-splice vector (Invitrogen). Human FGFR1 (21) was subcloned into pcDNA3.1 vector. Mutated (kinase dead) FGFR1 (Y653F/Y654F) was kindly provided by J. Schlessinger (Yale University School of Medicine, New Haven, CT) (22) . HA-ERK (23) was kindly provided by M. Karin (University of California, San Diego, CA). Plasmids encoding hSef-a and hSef-b mutated in the conserved tyrosine (Y330F and Y298F, respectively) were prepared each by a two-step PCR process. In the first step, two fragments were generated utilizing two separate PCR reactions with pcDNA3.1/Hygro-hSef-a as the template and primer sets p1/p2 and p3/p4, respectively (p1, 5Ј-AGAAAATATATTTT-CACATTTAGATG-3Ј and p2 reverse primer: 5Ј-ATTTCTC-CAAGACTGGCTCC-3Ј, p3: 5Ј-TCACTACAAGCTCAAG-CACGA-3Ј and reverse primer p4: 5Ј-CATCTAAATGTGAA-AATATATTTTCT-3Ј). The corresponding base change that replaces Tyr with Phe is underlined. The products of these two PCR reactions were used as the template for the second step PCR using primers p2 and p3. Following sequencing, the fragment with the mutation was liberated by PpuM1 and BstB1 digestion and used to replace the corresponding wild-type fragment in pcDNA3.1/Myc-His vector containing the cDNA of parental hSef-a or hSef-b digested with the same enzymes.
Generation of hSef-silencing Constructs-Three test small interference RNA sequences were identified according to the Whitehead siRNA Selection Web Server (24) and Oligoengine shockwave program as follows. shRNA 1: 5Ј-gatccccGTCGGAGGGAAGACAGTGCttcaagagaGCACTGTCTTCCCTCCGACttttta-3Ј, and complementary strand, 5Ј-agcttaaaaaGTCGGAGGGAAGACAGTGCtctcttgaaGCACTGTCTTCCCTCCGACggg-3Ј; shRNA 2: 5Ј-gatccccGCATGTGATTGCTGACGCCttcaagagaGGCGTCAGCAATCACATGCttttta-3Ј, and complementary strand, 5Ј-agcttaaaaaGCATGTGATTGCTGACGCCtctcttgaaGGCGTCAGCAATCACATGCggg-3Ј; and shRNA 3: 5Ј-gatccccAGCAGGAGCAAACTACAGAttcaagagaTCTGTAGTTTGCTCCTGCTttttta-3Ј; and complementary strand, 5Ј-agcttaaaaaAGCAGGAGCAAACTACAGAtctcttgaaTCTGTAGTTTGCTCCTGCTggg-3Ј. The control shRNA is the reverse orientation of shRNA 1. The 3Ј-and 5Ј-ends of the oligonucleotide primers were adapted for cloning into the BglII and HindIII site of the pSUPER vector (25) . Equimolar amounts of oligonucleotide pairs were annealed and ligated into pSUPER digested with BglII and HindIII. Positive clones were sequenced to ensure accuracy of RNA interference. The efficiency of RNA interference was initially tested by co-transfecting an hSef expression vector with each shRNA construct into HEK 293 cells using previously described transfection protocol (14) . Each Sef shRNA, but not the control shRNA or empty pSUPER vector, reduced hSef protein levels when compared with cells transfected with hSef construct alone (data not shown).
Cell Culture and Transfection Methods-Human embryonic kidney (HEK) 293 cells and HeLa cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. NIH 3T3 cells were grown in Dulbecco's modified Eagle's medium containing 10% newborn calf serum. Transient transfections in HEK 293 cells were performed with Lipofectamine Plus (Invitrogen). The total amounts of DNA in each transfection were normalized with the pcDNA3 plasmid. For co-immunoprecipitation (CO-IP), cells in 6-cm dishes were transfected with 3 g of receptor and hSef-a plasmids. For hSef-b, we used 10-cm dishes and higher plasmid concentrations (12 g of hSef-b and 4 g of receptor) to compensate for hSef-b low translation efficiency (14) . Stable transfections in NIH 3T3 were carried out with the calcium phosphate method as previously described (26) . Tet-off NIH 3T3 cells (S2-6 cells, gift from Dr. David G. Schatz, Yale University (27)) were cultured in histidine-deficient Dulbecco's modified Eagle's medium containing 0.5 mM L-histidinol, 10% serum, and 1 g/ml tetracycline. hSef-a Tet-off NIH 3T3 cell lines were established by co-transfection of the Tet-off cells with pTet splice-hSef-a or an empty vector, and pTK-hyg (Clontech) followed by selection in complete medium plus 150 g/ml hygromycin. Colonies of resistant cells were isolated 3 weeks post transfection. The generation of hSef-b Tet off NIH 3T3 cells was previously described (14) . The experiments described here were carried out with two to three individual clones and were repeated at least three times. To generate HeLa cells stably expressing hSef shRNA, subconfluent cultures were transfected with a combination of the three hSef shRNA constructs (1.5 g of each/plate) or the control shRNA construct (4.5 g/plate), together with pCDNA 3.1 for selection. Transfection was performed with DreamFect reagent according to the manufacturer's instructions (OZ Biosciences). Following selection with 0.5 mg/ml G418, mass cultures were tested for the reduction of endogenous hSef RNA. The most efficient reduction was observed with cells transfected with the combination of constructs. These cells were subsequently used for future studies.
RNA Extraction and Reverse Transcription-PCR-For detection of hSef transcripts in HeLa cells, total RNA was extracted as described previously (21) , and 1 g of total RNA was used for first-strand synthesis with random hexamer primers. Where indicated, amplification was performed with a reverse primer common to both hSef isoforms (5Ј-TGAAGCTACTGTT-GAGCTGCTTCG-3Ј) and isoform-specific forward primers (hSef-a, 5Ј-GAGGATCCTGACGGCCATGGCCCCGTGGC-TGCAGCTC-3Ј or hSef-b, 5Ј-GCGTGCCAGACAGAGTGC-TAGGCAT-3Ј) or with primers common to both hSef isoforms as previously described (14) . Glyceraldehyde-3-phosphate dehydrogenase amplification was used for monitoring RNA quantity and amplification efficiency.
Mitogenic, Proliferation, and Apoptosis Assays-[ 3 H]Thymidine incorporation assay was performed in 96-well microtiter plates essentially as described (20) . Confluent cultures were growth arrested in 0.3% serum for 24 h, and, where indicated, tetracycline was removed 24 h before stimulation with serum (10%) or growth factors. For apoptosis, NIH 3T3/hSef-a or hSef-b cells were grown for 48 h in the presence or absence of tetracycline, with 10% newborn calf serum or with FGF2 (0.25 ng/ml) in serum-free medium. Apoptosis was examined with a Leica DM IRE2 inverted fluorescence microscope, using the In Situ Cell Death detection kit (TUNEL staining, Roche Molecular Biochemicals). Nuclear staining was done with 5 g/ml Hoechst (Calbiochem). Proliferation assay was performed as previously described (28) . Briefly, HeLa cells stably expressing hSef shRNA or control shRNA were seeded into 35-mm plates (2.5 ϫ 10 4 cells/plate) in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. The following day, cells were washed with phosphate-buffered saline, and grown in Dulbecco's modified Eagle's medium alone or in the presence of desired concentrations of growth factors. Fresh growth factors were added every other day, and viable cells were counted on day 5 of incubation. Each data point was performed in duplicates or triplicates, and each experiment was repeated at least three times. Protein Detection, Co-immunoprecipitations, and Immunofluorescence-Polyclonal antibodies against hSef were generated as described (14) . CO-IP, immunoprecipitation, and immunoblotting were done essentially as described (28, 29) . For CO-IP of hSef-FGFR complexes, cells were lysed 24 h post transfection in HTNG buffer containing 20 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol, 1%Triton X-100, 1 mM EGTA, 1 mM NaVO 4 , and protease inhibitors. For immunoprecipitation of hSef, cells were lysed in radioimmune precipitation assay buffer containing 10 mM sodium phosphate, pH 7.4, 0.1 M NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 1 mM EGTA, 1 mM NaVO 4 , and protease inhibitors. Extracts clarified by centrifugation were incubated with antibodies. Immunocomplexes were captured on Protein G Dynabeads (Dynal) and washed with the corresponding buffer used for preparation of cell lysates. Following SDS-PAGE and immunoblotting, bound antibodies were visualized by chemiluminescence. For immunofluorescence, NIH 3T3 stably expressing hSef isoforms were plated on coverslips. The following day, cells were serumstarved (0.2% newborn calf serum) in the presence or the absence of 1 g/ml tetracycline for 17 h. Cells were then stimulated for 7 min with FGF2 (10 ng/ml) and fixed with 3% paraformaldehyde. Cells were permeabilized with ice-cold methanol, blocked with 5% horse serum, and labeled with antipErk mouse monoclonal antibodies (Cell signaling) followed by Rhodamine-Red TM -x-conjugated Affinipure goat anti-mouse IgG (Jackson ImmunoResearch). Fluorescence microscope analysis was performed with a Leica DM IRE2 inverted fluorescence microscope. Commercial antibodies used were: anti-Myc epitope mouse monoclonal antibodies (9E10), p38, MEK-1, Akt1/2, HA-probe, CDK4, Actin, and FGFR1 rabbit polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), phospho-p44/42 MAPK (Thr-202/Tyr-204) (E10), cyclin D1 mouse monoclonal antibodies, phospho-MEK1/2 (Ser-217/221) rabbit polyclonal antibodies (Cell Signaling Technology, Beverly, MA), p-Tyr clone 4G10 mouse monoclonal antibodies (UBI), phospho-Akt (Ser-473) rabbit polyclonal antibodies, diphosphorylated-p38 mouse monoclonal antibodies, goat antimouse or anti-rabbit IgG Peroxidase Conjugate (Sigma), Rhodamine-Red TM -x-conjugated Affinipure goat anti-mouse IgG (Jackson ImmunoResearch). Extracellular signal-regulated kinase (ERK) rabbit polyclonal antibodies were a gift from Y. Granot (Ben Gurion University, Beer-Sheva, Israel).
RESULTS

Human Sef Isoforms Are Phosphorylated on Tyrosine Residues When
Expressed with Activated FGFR-To examine the prediction that Sef can be phosphorylated on tyrosine and to study the requirements for such phosphorylation, we employed transient transfection assays in HEK 293 cells. Cells were trans-fected with Myc-tagged hSef-a or hSef-b constructs, with or without wild-type or kinase-dead FGFR1. Following CO-IP, blots were reacted with anti-pTyr antibodies, FGFR or Sef-specific antibodies. When expressed alone, neither hSef isoform was phosphorylated on tyrosine residues (Fig. 1A) . When coexpressed with FGFR1, both hSef variants formed a complex with the receptor, in agreement with previous studies (14) . Two phosphorylated bands were detected following the CO-IP in cells expressing hSef isoforms and FGFR1. The higher molecular mass band (ϳ130 kDa), common to both samples, was recognized by anti-FGFR1 antibodies. The other phosphorylated band was recognized by hSef or anti-Myc antibodies and had the expected molecular mass of each isoform, ϳ115 and 85 kDa for hSef-a and hSef-b, respectively (Fig. 1A) . To assess whether the invariant tyrosine is the major site of phosphorylation in hSef-a and to further explore its role in mediating hSef function, we substituted the invariant tyrosine with phenylalanine (Y330F). The mutant was still phosphorylated on tyrosine when co-expressed with wild-type receptor. The mutation, however, did not interfere with hSef/FGFR1 association (Fig. 1B) . As hSef-a and FGFR1 proteins migrated very closely, we also performed IP with anti-Myc tag antibodies under conditions that prevented the co-precipitation of the receptor to further confirm hSef tyrosine phosphorylation. Under these experimental conditions, a single phosphorylated band with the expected molecular weight of hSef-a or the hSef-a mutant was detected with the anti pTyr antibody and subsequently with the anti-Sef (data not shown) or anti-Myc antibodies (Fig. 1C) .
To determine whether active FGFR is essential for hSef phosphorylation we co-expressed hSef-a with a kinase-dead FGFR1 mutant. CO-IP was performed with anti-Myc epitope tag antibodies. hSef-a was associated with the kinase-dead FGFR, but it was not phosphorylated on tyrosine (Fig. 1D ). Taken together, the results revealed that hSef is a Tyr-phosphorylated protein, whose phosphorylation depends on an activated FGFR.
Effect of hSef-a on Proliferation of NIH 3T3 Cells and the Spectrum of Its Inhibitory
Activity-NIH 3T3 cells, extensively utilized as a model to study oncogenesis, regulation of cell proliferation and growth factor-mediated signaling, were chosen to study the regulatory effects of hSef-a. We established stable NIH 3T3 clones where the expression of hSef-a is regulated by tetracycline (tet). Clones that expressed the weakest hSef-a protein levels in the presence of tet were chosen for further analysis. Maximal level of hSef-a protein was obtained 16 h following removal of tet ( Fig. 2A and data not shown). [ 3 H]Thymidine incorporation assays were employed to explore the effect of hSef-a on the ability of serum-starved quiescent NIH 3T3 cells to re-enter the cell cycle following stimulation with FGF2. The mitogenic activity of FGF2 was strongly inhibited in cells expressing hSef-a but not in cells transfected with the control vector (Fig. 2, B and C) . Similar results were obtained with two additional NIH 3T3/hSef-a clones. These findings indicate that one mechanism by which hSef-a acts, is restricting cell division.
Next, we examined the spectrum of the inhibitory activity of hSef-a. Quiescent NIH 3T3/hSef-a cells, or control cultures, were stimulated with additional members of the FGF family, as well as a subset of other RTK ligands or serum. A dose-response curve was performed for each ligand, and representative results are shown in Fig. 2 . In addition to FGF2, hSef-a inhibited the mitogenic activity of FGF1 and FGF4 (85% inhibition of FGF2 and 50% inhibition of FGF1 and FGF4) but had little or no effect on the activity of serum, epidermal growth factor (EGF) or insulin (Fig. 2, D and E) . These results point to the selectivity of hSef-a inhibitory activity toward FGFs in NIH 3T3 cells.
Effect of hSef-a on Cyclin D1 Levels-The hSef-a-inducible cell lines were utilized to explore the mechanism by which hSef-a inhibits cell growth. Induction of cyclin D1 expression is one of the earliest cell cycle-related events to occur during the G 0 /G 1 to S-phase transition (30, 31) . Because hSef-a inhibited FGF-induced S-phase entry, we initially examined its effect on FIGURE 1. hSef is phosphorylated on tyrosine in an activated FGFR-dependent manner. HEK 293 cells were transiently transfected with the indicated constructs. Cells were stimulated with FGF for 10 min, and then lysed in HTNG buffer or radioimmune precipitation assay buffer. Whole cell lysates (WCL) were either immunoblotted (WB) with anti-p-Tyr (␣p-Tyr), anti-FGFR1 (␣R1), anti-hSef or anti Myc tag antibodies, or immunoprecipitated (IP) with anti-Myc tag antibodies as described under "Experimental Procedures." Samples subjected to IP were subsequently immunoblotted with antibodies to p-Tyr, R1, Myc or hSef. A, both hSef-a (Sa) and hSef-b (Sb) gene products are phosphorylated on tyrosine when co-expressed with activated FGFR. Cells transfected with the indicated constructs were lysed in HTNG buffer; B and C, mutant hSef-a Y330F is still phosphorylated on tyrosine when co-expressed with FGFR. Cells lysates were prepared using HTNG (B) or radioimmune precipitation assay (C) buffer. Note that FGFR1 was not co-precipitated with hSef-a or the hSef-a mutant when cells were lysed in radioimmune precipitation assay buffer; D, activated FGFR is required for hSef-a phosphorylation, but not hSef/receptor association. Cells were transfected with each hSef-a or kinase-dead FGFR mutant (kd) or co-transfected with hSef-a/kd receptor mutant or hSef-a/wild-type receptor. Cells were lysed in HTNG buffer. IP samples (lanes 5-7) correspond to the WCL in lanes 1-3, respectively. The abbreviations a, b, R1, a*, and wt denote hSef-a, hSef-b, FGFR1, hSef-a Y330F mutant, and wild-type constructs, respectively. The data are representative of at least three independent experiments. the levels of cyclin D1 protein during cell cycle progression. Growth-arrested NIH 3T3/hSef-a cells were stimulated with FGF2, and cyclin D1 protein levels were evaluated at different time intervals post growth factor stimulation. Cyclin D1 protein was readily observed in FGF2-treated NIH 3T3/hSef-a cells grown in the presence of tet, whereas it was hardly detected in FGF2-treated cells induced to express hSef-a (Fig. 3A) . Because the levels of cyclin-dependent kinase 4 (CDK4) do not fluctuate during the cell cycle (30), we used CDK4 as a probe for protein levels at each time point. CDK4 levels were similar in all time points in cultures grown with, and without, tet (Fig. 3A) . In addition, the levels of cyclin D1 remained unchanged in the control cells grown with or without tet (data not shown). (Fig. 3B, lanes 1 and 2) , previously identified as SNT/FRS2 and phospholipase C␥, respectively (28, (32) (33) (34) (35) ). An identical phosphorylation pattern was observed in the presence of hSef-a in cells stimulated over a wide range of FGF2 concentrations (Fig. 3B, lanes 4 -6) . These results indicate that hSef-a does not inhibit FGFR activity.
Effect of hSef-a on FGF-mediated
To further explore the mechanism by which hSef-a inhibited FGF-mediated NIH 3T3 proliferation, we investigated its effect on FGF2-induced activation of ERK/ MAPK, PKB/Akt, and p38 MAPK. These three kinases are activated in FGF-stimulated NIH 3T3 cells, and their concerted action is required to mediate the mitogenic response of NIH 3T3 cells to FGF (Ref. 14 and data not shown). In addition, inhibition of either the ERK/MAPK or PKB/Akt, as well as overstimulation of p38 MAPK, are known to downregulate cyclin D1 levels (30, 31, 36) . Serum-starved NIH 3T3/hSef-a cells, grown in the presence or absence of tet, were stimulated with FGF for different time intervals, and the effect of hSef-a on the activation state of each of the three kinases was studied utilizing antibodies that specifically recognize their activated forms. Stimulation over time, of control or hSef-a-expressing cells, revealed that hSef-a inhibited FGF2-induced activation of PKB/Akt (Fig. 3C ). ERK1/2 phosphorylation, however, either transient or sustained, was not affected by hSef-a (Fig. 3D, top  and bottom panels) . As a control for ERK1/2 inhibition, we compared the effect of hSef-b to that of hSef-a. hSef-b readily FIGURE 2. hSef-a inhibits FGF-induced mitogenic activity. A, induced expression of hSef-a in the tet-off NIH 3T3 cells. Cells were grown in 10% serum in the presence or absence of 1 g/ml tet for 24 h. The cells were lysed, and hSef-a expression was analyzed by immunoblotting with hSef-specific antibodies. Control cultures denote parental cells transfected with an empty pTet-splice vector. The experiments described in the present study were performed with at least two hSef-a-expressing clones and repeated between two or three times. B and C, hSef-a inhibits the mitogenic activity of FGF2. Confluent cultures of control cells (B) or hSef-a-expressing cells (C) were serum-starved and grown in the presence or absence of tet for 24 h. FGF2 was added at the indicated concentrations. [ 3 H]Thymidine incorporation assay was performed as described (20) . D and E, the spectrum of inhibitory activity of hSef-a. Mitogenic assay in control cultures (D) or cells expressing hSef-a (E) was performed as described in B and C. The -fold increase in biological activity was calculated by dividing cpm values obtained in the presence of the indicated stimulators with those obtained in 0.3% serum alone. Percent [ 3 H]thymidine incorporation is relative to the -fold increase obtained in cultures stimulated with 10% serum in the presence of tet that was set at 100%. The concentrations of FGFs (F), insulin (INS), epidermal growth factor (EGF), and serum (NBS) are those that gave rise to a maximal biological response.
inhibited ERK1/2 phosphorylation in NIH 3T3 cells (Fig. 3E ), in agreement with previous studies (14) .
In addition to inhibiting the activation of PKB/Akt, hSef-a enhanced the levels of phospho-p38 MAPK as compared with its phosphorylation levels in FGF-stimulated control cultures or NIH 3T3/hSef-a cells grown in the presence of tet (Fig. 4A) . Quantification of phospho-p38 levels in these cell cultures indicated that p38-MAPK phosphorylation was increased by 2.7-and 6-fold after 1 and 5 min of FGF stimulation, respectively, in hSef-a-expressing cells (Fig. 4B) .
It has been demonstrated that in certain cell types the PI3K/ Akt pathway regulates p38 activation. To explore whether hSef-a inhibition of PKB/Akt is responsible for the overstimulation of p38 MAPK, we tested whether the two kinases crosstalk in NIH 3T3 cells. To this end, the PI3K/Akt pathway was inhibited with wortmannin (3, 37) , and the effect of Akt inhibition on the activation state of p38 MAPK was assessed. NIH 3T3/hSef-a cells grown in the presence or absence of tet were either treated with wortmannin or left untreated. Then, the cells were stimulated with FGF for 2.5 min, and the levels of activated PKB/Akt and p38 were determined in whole cell lysates. In agreement with the above results, in hSef-a-expressing cells, FGF stimulation resulted in a reduction in PKB/Akt phosphorylation and in overstimulation of p38 phosphorylation (Fig. 4C  compare lane 1 to lane 3) . Wortmannin treatment completely inhibited FGF-induced PKB/Akt activation (see Fig. 4C, lanes 2 and 4) , but this did not lead to overstimulation of p38 MAPK beyond the levels observed in cells untreated with wortmannin (Fig.  4C ). These findings indicate that the PI3K/Akt pathway does not regulate p38 activation in NIH 3T3 cells, in agreement with the study by Zhuang et al. (38) . Moreover, these results clearly indicate that the effect of hSef-a on p38 MAPK is independent from its effect on PKB/Akt.
hSef-a Promotes Apoptosis in FGF-stimulated Cells-Overstimulation of p38 MAPK is associated not only with growth arrest but also with apoptosis (3, 39) . The hSef-amediated increase in p38 activation encouraged us to examine whether hSef-a, by virtue of its effect on this kinase, would mediate apoptotic cell death. NIH 3T3/hSef-a cells were stimulated with serum or FGF, in the presence or absence of tet. The effect of hSef-a on apoptosis was then examined at different time intervals following stimulation, utilizing TUNEL staining. Representative results are shown in Fig. 5 . hSef-a induced apoptosis in Ͼ95% of FGF-stimulated cells grown in the absence of tet. Very few apoptotic cells were observed in FGF-stimulated cultures grown in the presence of tet, or cells grown in the presence of serum, with or without tet (Fig. 5, A, B , and E). An inhibitor of the ␣ and ␤ isoforms of p38 MAPK (SB203508), which are known to be expressed in NIH 3T3 cells (40, 41) , abrogated the effect of hSef-a on apoptotic cell death (Fig. 5, C and E) . Previously, we reported that hSef-b does not induce apoptosis in serum-stimulated cells (14) . Our present results led us to examine whether hSef-b can mediate apoptosis in an FGF-dependent manner. Unlike hSef-a, the hSef-b isoform failed to induce apoptosis in NIH 3T3/hSef-b cells stimu- FIGURE 3 . A, the effect of hSef-a on cyclin D1 levels. NIH 3T3/hSef-a cells were serum-starved for 24 h, in the presence or absence of tet, and then stimulated with FGF2 (20 ng/ml) for the indicated time periods. The levels of cyclin D1 were evaluated in total cell lysates over 20 h of stimulation. Cyclin D1 and CDK4 proteins were analyzed by immunoblotting with anti-cyclin D1 monoclonal antibodies or rabbit anti-CDK4 polyclonal antibodies, respectively. B, hSef-a does not inhibit the phosphorylation of FGFR substrates. hSef-a-inducible NIH 3T3 cells were serum-starved for 24 h, in the presence or absence of tet, and then left unstimulated or stimulated for 10 min with FGF2 at the following concentrations: lane 2, 200 ng/ml; lanes 4 and 6, 20, 50, or 200 ng/ml. Equal amounts of whole cell lysates were analyzed by immunoblotting with anti-p-Tyr antibodies. C-E, the effect of hSef-a on the activation of PKB/Akt (C) and MAPK (D and E). Control, hSef-a-or hSef-b-inducible NIH 3T3 cells were serum-starved for 24 h, in the presence or absence of tet, and then stimulated with FGF2 (20 ng/ml) for the indicated time periods. Equal amounts of whole cell lysates were analyzed by immunoblotting. The membranes were successively incubated with the indicated antibodies. lated with FGF2 (Fig. 5, D and E) . Under the same conditions, hSef-b inhibited FGF2-induced bromodeoxyuridine incorporation and MAPK activation (data not shown). These results reveal a differential effect of hSef isoforms on apoptosis and clearly demonstrate that hSef-a-mediated apoptosis depends on FGF stimulation.
Effect of hSef-a on ERK Nuclear Translocation-A recent study suggested that hSef-a does not inhibit MAPK activation, but it prevents the nuclear translocation of activated MAPK (18) . We therefore examined the effect of hSef-a on the subcellular localization of MAPK in FGF2-stimulated NIH 3T3/hSef-a cells. In a parallel experiment, we assessed the ability of hSef-a to inhibit FGF2-induced mitogenic response, as a positive control for hSef-a activity in the assay. Cells were serum-starved in the presence or absence of tet and then stimulated with FGF. MAPK nuclear translocation was assessed by immunofluorescence using antibodies directed against activated MAPK. Representative results are shown in Fig. 6 . Although hSef-a readily inhibited FGF2-induced mitogenic response, no apparent difference was observed in the nuclear translocation of activated MAPK between hSef-a-expressing cells and control cultures stimulated with FGF2 (Fig. 6, A and B, and data not shown) . Unlike hSef-a, hSef-b efficiently inhibited nuclear translocation of activated MAPK, as anticipated from the hSef-b-inhibitory effect on MAPK activation (Fig. 6, A and B) .
hSef-a Inhibits the Activation of MAPK in HEK 293
Cells-The inability of hSef-a to inhibit MAPK activation and nuclear translocation in FGF-stimulated NIH 3T3/hSef-a cells prompted us to determine whether hSef-a can affect MAPK activation in a different cell type. The effect of hSef-a was compared with that of hSef-b. HEK 293 cells were transiently transfected with FGFR1 expression vector, with or without hSef-a, or hSef-b constructs. As shown in Fig. 6C , hSef-a readily inhibited the activation of endogenous MAPK, but it had no effect on the activation of endogenous MEK. hSef-b inhibited MAPK activation in HEK 293 cells in accordance with its effect on MAPK activation in NIH 3T3 cells (Fig.  6D) . Similar inhibition was observed with HA-ERK (data not shown). Furthermore, hSef-a or hSef-b mutated in the conserved tyrosine retained the capacity to inhibit MAPK activation in HEK 293 cells (Fig. 6, C and D) . These findings suggest that hSef-a is fully capable of inhibiting MAPK activation and that this function is cell type-dependent.
Silencing of hSef Expression in HeLa Cells Facilitates Cell Proliferation and Enhances ERK/MAPK Phosphorylation-
The inhibitory effect of ectopically expressed hSef on cell cycle progression strongly suggested a role for hSef in constraining proliferation. Suppression of endogenous hSef expression would, therefore, be expected to accelerate cell growth. The pSUPER system for RNA interference was utilized to stably express hSef shRNA in HeLa cervical carcinoma cells. These cells predominantly express hSef-a (Fig. 7A) . Reverse transcription-PCR analysis with hSef-a-specific primers demonstrated that hSef-a transcript levels were substantially reduced in cells stably expressing hSef shRNA but not in cells expressing the control shRNA (Fig. 7B) . Similar results were obtained with hSef primers common to both hSef isoforms (data not shown). The proliferation rate of the transfected cells in serum-free conditions, in the presence of EGF (20 ng/ml), FGF1 (10 or 20 ng/ml), or FGF7 (10 ng/ml), was determined. The results clearly demonstrate that hSef silencing enhances proliferation of HeLa cells by 2-to 3-fold in serum-free conditions and following exogenous ligand stimulation (Fig. 7C) . These results establish that endogenous hSef exerts a growth constraining effect that is relieved upon hSef down-regulation.
HeLa shRNA cells were further utilized to examine the effect of endogenous hSef on FGF-stimulated ERK/MAPK phosphorylation. HeLa cells stably expressing Sef shRNA and the control cultures were stimulated with increasing concentrations of FIGURE 4. The effect of hSef-a on p38 MAPK activation. A and B, hSef-a or control inducible NIH 3T3 cells were serum-starved for 24 h in the presence or absence of tet, and then stimulated with FGF2 (20 ng/ml) for the indicated time periods. Whole cell lysates were analyzed by immunoblotting as described in the legend to Fig.  3 . The extent of p38 phosphorylation was quantified using Tina software (B). C, lack of cross-talk between the PI3K and the p38 MAPK pathways in NIH 3T3 cells. hSef-a-inducible NIH 3T3 cells were serum-starved for 24 h, in the presence or absence of tet, and then stimulated with FGF2 (20 ng/ml) for 2.5 min in the presence or absence of wortmannin. Whole cell lysates were analyzed by immunoblotting, as described in the legend to Fig. 3 . Lanes 1 and 3, cells were stimulated with FGF alone; lanes 2 and 4, cells were treated with 300 nM wortmannin 30 min prior to stimulation with FGF2.
EGF for 10 min, and MAPK phosphorylation was assessed in total cell lysates. As shown in Fig. 7D , a significant increase in p-ERK levels was apparent in cultures stably expressing hSef shRNA as compared with the control cultures. This difference, however, was the highest in cells stimulated with low EGF concentration (10 ng/ml), whereas at the highest concentration (180 ng/ml) the difference was no longer apparent. The increase in p-ERK levels was also clearly apparent in shRNA cultures stimulated over time in the presence of 10 or 20 ng/ml EGF (Fig. 7E and data not shown) . Unlike the situation with MAPK, hSef knockdown had no significant effect on MEK phosphorylation (Fig. 7D) .
DISCUSSION
Negative feedback regulation is an important mechanism evolved to restrict or attenuate RTK-mediated signaling to guarantee the proper functioning of multicellular organisms (1). Numerous studies were focused on understanding the regulation of the Ras/MAPK pathway by feedback antagonists, but only little is known about the modulation of other signaling pathways by these antagonists. Sef is a recently identified feedback antagonist of RTK signaling that in human encodes a membranal and a cytosolic isoform (14) . In the present work, we provide the first comprehensive analysis of the biological properties and mode of action of the membranal isoform of human Sef (hSef-a). Our results clearly show that hSef-a is a multifunctional protein that can modulate three different FGFmediated signaling pathways. In addition, our results point to similarities, as well as considerable differences, between the mode of action of the two hSef isoforms and their subsequent effect on cellular responses to FGF.
In NIH 3T3 fibroblasts, one effect of hSef-a was the inhibition of FGF-dependent mitogenic response. hSef-a did not inhibit the response to serum and other RTK ligands, such as insulin and EGF, suggesting that in these cells hSef-a selectively affects FGF signaling. These effects of hSef-a were accompanied by inhibiting the activation of PKB/Akt and up-regulation of p38 MAPK activity. The observation that the PI3K/Akt pathway does not have cross-talk with the p38 MAPK pathway in NIH 3T3 cells further implies that hSef-a independently regulates the activation state of PKB/Akt and p38 MAPK. Reduced PKB/Akt activity and enhanced activity of p38 are known to down-regulate cyclin D1 levels and to subsequently induce growth arrest (30, 31, 36) . Consistent with this is the finding that hSef-a down-regulated cyclin D1 levels. Taken together, the current results support a model whereby hSef-a regulates cell growth by modulating the activity of key kinases involved in cell cycle progression. Our hSef RNA interference studies in HeLa cells further confirm a role for endogenous hSef-a in attenuating cell proliferation. Interestingly, in NIH 3T3 cells, hSef-a had no effect on the activation of MAPK, another important modulator of cyclin D1 levels and cell proliferation (30, 31, 36) . In this respect hSef-a differed from hSef-b, which mediated growth arrest in NIH 3T3 cells by inhibiting the activation of MAPK (14) . Thus, in NIH 3T3 cells hSef isoforms utilize different mechanisms to induce growth arrest.
In addition to its inhibitory effect on FGF-induced cell proliferation, hSef-a induced apoptosis in NIH 3T3 cells following stimulation with FGF. hSef-a did not induce apoptosis of serum-stimulated cells, in accordance with its inability to inhibit the mitogenic response of NIH 3T3 to serum. Upregulation of p38 plays a central role in mediating the effect of hSef-a on cell survival, because a specific inhibitor of p38 completely abrogated hSef-a pro-apoptotic effect. The current finding that hSef-b failed to induce apoptosis, in conjunction with its previously reported inability to enhance FGF-induced p38 MAPK activation (14) , further supports a role for the increased p38 activity in mediating the pro-apoptotic effect of hSef-a in NIH 3T3 cells. In addition, it is well documented that elevated p38 signal mediates apoptosis in a variety of cell types, including Ras transformed NIH 3T3 cells, PC12 cells, and cardiomyocytes (39, (41) (42) (43) (44) . Downregulation of PKB/Akt, together with up-regulation of p38 was reported to be involved in apoptosis in different cell types, and the PI3K pathway was reported to control p38 activation in certain cell types (38, 45) . It is currently unknown whether hSef-a-mediated inhibition of PKB/Akt contributes to hSef-a pro-apoptotic effect. The full protective effect of the p38 MAPK-specific inhibitor suggests that reduced pKB/Akt activity by itself is not sufficient for hSefa-mediated apoptosis. Moreover, if PKB/Akt inhibition contributes to hSef-a-driven apoptosis, this does not involve steps upstream of p38, because Akt does not control p38 activation in NIH 3T3 cells (current studies and Ref. 38 ). Similar to hSef-a, the mouse orthologue was reported to induce apoptosis in HEK 293 cells, but unlike hSef-a, this effect was independent of growth factor stimulation and involved JNK activation (46) . This suggests that Sef can mediate apoptosis via the activation of different proapoptotic MAPKs.
Whether or not Sef can inhibit the activation of MAPK is a controversial issue. Studies by different groups suggested that zfSef, mSef, and hSef-a inhibit the activation of MAPK, whereas a recent study by Torii et al., suggested that hSef-a does not affect MAPK activation, but it prevents the subsequent nuclear translocation of activated MAPK (11, 13, 15, 16, 18 (16, 19) . Thus, both hSef isoforms inhibited MAPK activation without affecting the upstream MEK in HEK 293 cells. Similar results were previously obtained for hSef-b in NIH 3T3 cells (14) . Consistent with this, hSef-a had no effect on upstream components of FGFR signaling, and hSef knock- A, hSef-a-or hSef-b-inducible NIH 3T3 cells were serum-starved for 17 h, in the presence or absence of tet. Cells were then stimulated with FGF2 (F2, 10 ng/ml) for 7 min or left unstimulated. Cells were fixed and stained with anti-p-ERK antibodies, followed by Rhodamine-conjugated goat anti-mouse antibodies. More than 300 cells were examined in terms of localization of endogenous p-ERK in the nucleus. B, quantification of p-ERK nuclear translocation. The criterion for inhibition of nuclear translocation was background staining in the nucleus, or at least 50% reduction as compared with the control cultures. In hSef-a-expressing cells, fluorescence intensity in the nucleus was identical to that of control cultures stimulated with FGF. The effect of hSef isoforms on MAPK activation in HEK 293 cells. HEK 293 cells were co-transfected with 0.1 g of FGFR1 and the indicated concentrations of hSef isoforms constructs. DNA amounts were normalized with pcDNA3.1. Cells were stimulated with FGF2 (100 ng/ml) for 15 min. Equal amounts of whole cell lysates were analyzed by immunoblotting. The membranes were successively incubated with the indicated antibodies. p-Erk and p-Mek are antibodies directed against the phosphorylated (p) form of the kinases. C, the effect of hSef-a and the hSef-a* mutant. D, the effect of hSef-b and the hSef-b* mutant. hSef-a* and hSef-b* denote hSef mutated in the conserved tyrosine. The data are representative of at least three independent experiments. down in HeLa cells increased growth factor-dependent MAPK phosphorylation, without affecting MEK activation.
The current findings point to the existence of variations between the mechanism by which Sef orthologues exert their inhibitory effects. The different consequence of mutating the conserved tyrosine in hSef-a versus its zebrafish orthologue is one example. In zebrafish, this mutation abolished activity, whereas the corresponding mutation in both hSef isoforms did not affect their ability to inhibit MAPK in HEK 293 cells (current results) or hSef-a ability to attenuate FGF-dependent mitogenic response in NIH 3T3 cells (18) . The hSef-a and mSef orthologues, when expressed in fibroblasts, both inhibited the PI3K/Akt pathway and attenuated FGF-dependent mitogenic response (current results and Ref. 13 ). Yet only mSef inhibited FGFR and MAPK activation in these same cells (13) . Similarly, the two hSef isoforms, as shown here, differ in many aspects of their mechanism of action in addition to their cellular contextdependent effects. The fact, that the two hSef isoforms as well as hSef-a/mSef share similar but also distinct activities when expressed in the same background, strongly suggests that the differences between them are inherent. The reason for these differences is not clear at present, but their existence strongly indicate that one cannot generalize Sef mechanism of action by studying Sef from one species, one Sef isoform and in one cell type.
We have demonstrated, for the first time, that Sef is indeed a phosphoprotein. Both hSef isoforms were phosphorylated on tyrosine when coexpressed with activated FGFR but not when expressed alone. Moreover, our results also indicate that hSef contains more than one site for tyrosine phosphorylation, because an hSef-a mutated in the conserved tyrosine was still recognized by anti-phosphotyrosine antibodies. In accordance with these findings, amino acid sequence analysis of hSef predicted several such putative sites, in addition to the invariant tyrosine (data not shown). Apparently, active FGFR was essential for hSef tyrosine phosphorylation but not for hSef/receptor association. These findings, in conjunction with the lack of an hSef-a effect on phosphorylation of FGFR substrates, could imply that hSef/receptor association is required for FGFR-mediated Sef phosphorylation. Another function that could be attributed to hSef/receptor association is to bring cytosolic Sef isoforms, such as hSef-b, into close proximity with their membranal effectors. The dependence of hSef modulatory effects on ligand stimulation, together with the known function of phosphorylated tyrosine residues to serve as docking sites for signaling molecules (1), suggest that Sef phosphorylation may be required to mediate its inhibitory activity. Studies are underway to address this question.
In summary, the present study revealed the multifunctional nature of hSef-a. This hSef isoform can regulate at least three intracellular signaling pathways involved in cell cycle progression and cell survival, including the PI3K/Akt, p38-and ERK-MAPK pathways. hSef-a inhibition of ERK-MAPK activation depends on cellular context. In addition, our study revealed that hSef isoforms can regulate signal specificity and subsequent biological outcome by utilizing distinct mechanisms to modulate cellular responses to FGF. A challenging avenue of future research would be to elucidate the molecular mechanisms underlying the differential regulation of the PI3K and the p38 MAPK pathways by the two hSef isoforms and to reveal the mechanism underlying the cell type-specific modulation of MAPK activity by hSef-a.
